XLO vs. PRQR, MCRB, RGLS, CNTX, VERU, RPTX, CYBN, SCPH, RAPT, and SYRS
Should you be buying Xilio Therapeutics stock or one of its competitors? The main competitors of Xilio Therapeutics include ProQR Therapeutics (PRQR), Seres Therapeutics (MCRB), Regulus Therapeutics (RGLS), Context Therapeutics (CNTX), Veru (VERU), Repare Therapeutics (RPTX), Cybin (CYBN), scPharmaceuticals (SCPH), RAPT Therapeutics (RAPT), and Syros Pharmaceuticals (SYRS). These companies are all part of the "pharmaceutical preparations" industry.
Xilio Therapeutics (NASDAQ:XLO) and ProQR Therapeutics (NASDAQ:PRQR) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, earnings, risk, valuation, profitability, community ranking, media sentiment and analyst recommendations.
In the previous week, ProQR Therapeutics had 1 more articles in the media than Xilio Therapeutics. MarketBeat recorded 2 mentions for ProQR Therapeutics and 1 mentions for Xilio Therapeutics. Xilio Therapeutics' average media sentiment score of 1.38 beat ProQR Therapeutics' score of 1.23 indicating that Xilio Therapeutics is being referred to more favorably in the media.
ProQR Therapeutics received 315 more outperform votes than Xilio Therapeutics when rated by MarketBeat users. However, 73.33% of users gave Xilio Therapeutics an outperform vote while only 61.86% of users gave ProQR Therapeutics an outperform vote.
ProQR Therapeutics has higher revenue and earnings than Xilio Therapeutics. ProQR Therapeutics is trading at a lower price-to-earnings ratio than Xilio Therapeutics, indicating that it is currently the more affordable of the two stocks.
Xilio Therapeutics has a beta of -0.13, indicating that its share price is 113% less volatile than the S&P 500. Comparatively, ProQR Therapeutics has a beta of 0.3, indicating that its share price is 70% less volatile than the S&P 500.
54.3% of Xilio Therapeutics shares are held by institutional investors. Comparatively, 32.7% of ProQR Therapeutics shares are held by institutional investors. 5.2% of Xilio Therapeutics shares are held by insiders. Comparatively, 8.4% of ProQR Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Xilio Therapeutics has a net margin of 0.00% compared to ProQR Therapeutics' net margin of -260.75%. ProQR Therapeutics' return on equity of -61.58% beat Xilio Therapeutics' return on equity.
ProQR Therapeutics has a consensus price target of $3.38, indicating a potential upside of 73.08%. Given ProQR Therapeutics' higher probable upside, analysts clearly believe ProQR Therapeutics is more favorable than Xilio Therapeutics.
Summary
ProQR Therapeutics beats Xilio Therapeutics on 11 of the 16 factors compared between the two stocks.
Get Xilio Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for XLO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding XLO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Xilio Therapeutics Competitors List
Related Companies and Tools
